BioCentury | Nov 30, 2020
Finance

Kinaset jumps into severe asthma with $40M to develop inhaled JAK inhibitor

Kinaset is launching with a $40 million series A led by  5AM Ventures and Atlas Venture with participation from Gimv to develop an inhaled immunomodulator that will compete with biologics in severe...
BioCentury | Nov 24, 2020
Deals

OncoImmune's choice to repurpose GvHD program for COVID pays off via $425M takeout by Merck

OncoImmune’s move to repurpose its GvHD program for COVID-19 has paid off via a takeout by Merck for $425 million up front. Under the deal, which includes undisclosed milestones and royalties, Merck & Co. Inc....
BioCentury | Nov 20, 2020
Deals

China in-licensing play LianBio follows $310M crossover round with broad Pfizer deal

Pfizer’s deal with LianBio will provide the Perceptive-backed, cross-border start-up with a commercial infrastructure in China, while giving the pharma a drug hunter and development partner led by veteran China biotech executives Bing Li and Debra...
BioCentury | Nov 14, 2020
Deals

Innovation in a hurry: China biotechs see a fast track to global stage – survey

The Chinese biopharma landscape in five years will see a majority of the money magnet companies commanding innovation, with first-in-class targets filling their pipelines and innovative biologics outpacing...
BioCentury | Nov 12, 2020
Product Development

Russian vaccine data add to expectations for COVID-19 vaccine efficacy set by BioNTech, Pfizer; Moderna readout coming

The first interim Phase III readout for Sputnik V suggests the Russian COVID-19 vaccine and BNT162b2 from BioNTech and Pfizer have similar efficacies as an interim analysis that will reveal whether Moderna...
BioCentury | Nov 5, 2020
Product Development

Data Byte: BCMA stands out at ASH 2020

As the BCMA race takes shape at ASH 2020, J&J is maintaining a leading position with the latest data for its CAR T cell candidate (cilta-cel), that is partnered with Legend. Updated data for at...
BioCentury | Oct 31, 2020
Translation in Brief

A method to collect tumor-specific T cells; plus research from Heidelberg University, Black Diamond, KSQ and SynDevRx

Isolating tumor antigen-specific T cellsScripps Research Institute scientists have described in Cell a method, coined FucoID, to detect and separate T cells that react to tumor-specific antigens from bystander T cells. In FucoID, which is based on...
BioCentury | Oct 29, 2020
Finance

Perceptive-backed in-licensing play LianBio to cast a wide net with $310M crossover round

A $310 million crossover round will enable Chinese in-licensing play LianBio to “cast a wide net” as it looks to build a broad portfolio, Perceptive’s Adam Stone told BioCentury. Perceptive Advisors seeded,...
BioCentury | Oct 27, 2020
Product Development

Mirati impresses with KRAS inhibitor response rates, potential biomarker

Mirati’s shares rose to an all-time high on Monday after the company dropped the latest response rate data in the closely-watched KRAS inhibitor race, but it’s still too early to tell how adagrasib (MRTX849) will...
BioCentury | Oct 21, 2020
Deals

Seeking programs underserved by traditional VCs, MD Anderson launches fund to support trials

A new fund co-founded by MD Anderson is intended to support early development of a subset of drug candidates that are not served by traditional venture capital or biopharmas, but which the cancer research...
Items per page:
1 - 10 of 4910